Navigation Links
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication
Date:12/29/2010

to bloody stools, severe diarrhea and frequent abdominal pain. Tiny open sores, or ulcers, form on the surface of the lining where they bleed and produce pus and mucus. Symptoms of the disease may lead to loss of appetite, subsequent weight loss, and fatigue.  UC is a chronic disease, and there is no cure.  Although progress has been made in inflammatory bowel disease (IBD) research, investigators do not know what causes this disease.

About REMICADE

REMICADE was the first anti-tumor necrosis factor (TNF)-alpha treatment to be approved in three different therapeutic areas: gastroenterology, rheumatology and dermatology.  REMICADE has demonstrated broad clinical utility with indications in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO).  The safety and efficacy of REMICADE have been well established in clinical trials over the past 17 years and through commercial experience with more than one million patients treated worldwide.

In the U.S., REMICADE is approved for the following indications:

  • Reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active RA, when administered in combination with methotrexate.  
  • Reducing signs and symptoms in patients with active AS.
  • Reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active CD who have had an inadequate response to conventional therapy.  
  • Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD.  
  • Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal heal
    '/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
2. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
3. Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI® Label to Include Inhibition of Structural Damage in Treatment of Psoriatic Arthritis
4. Centocor Ortho Biotech Inc. Announces NDA Submission for Abiraterone Acetate for the Treatment of Metastatic Advanced Prostate Cancer
5. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
6. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
7. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
8. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
9. ORTHO EVRA(R) Prescribing Information Updated
10. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
11. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... NEW YORK and PLAINSBORO, ... Nordisk announced today its support of the National ... in Care , which provides support to people ... the physical and psychosocial challenges that can impede ... of six modules, Communication With Your Provider ...
(Date:9/18/2014)... and MELBOURNE, Australia , Sept. ... Biopharma today announced the appointments of Dr. Ashraf ... D.V.M ., M.S., to its Board of Directors. Dr. ... Affairs Finance at Genentech and Chief Financial Officer for ... as Vice President and Global Head of Business Development ...
(Date:9/18/2014)... NEW YORK , Sept. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... James to the position of  Senior Director of ... Clinical Research, Mr. James has established and led successful ... Europe , to facilitate the clinical development ...
Breaking Medicine Technology:Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... 2011 Egenix, Inc. -- Donald Fresne, CEO ... appointment of Nils Bergenhem, PhD as President and ... of drug development experience to the company and ... between equally-sized companies, as well as between biotech ...
... Caremark Corporation (NYSE: CVS ) will be ... at 8:30 a.m. (ET) with analysts and investors to ... (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) An audio webcast of the ... Relations portion of the CVS Caremark Web site for ...
Cached Medicine Technology:Nils Bergenhem, PhD - Newly Appointed President and Chief Scientific Officer of Egenix, Inc. 2CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call 2
(Date:9/18/2014)... (PRWEB) September 18, 2014 Research conducted ... Allegheny Health Network has documented improved survival ... surgical removal of the tumors along with stereotactic radiosurgery. ... of ASTRO (American Society for Radiation Oncology) ... uses numerous precisely focused radiation beams to treat tumors ...
(Date:9/18/2014)... Johannesburg, South Africa (PRWEB) September 18, 2014 ... organization to adopt the HABIT™ Program in ... by Indaba Health and Wellness, and distributed in South ... version of the HABIT program, which has been tailored ... , IHW HABIT™ focuses on behavior modification and chronic ...
(Date:9/18/2014)... Springs, LA (PRWEB) September 18, 2014 This past ... got a kiss from Roy at the kissing booth during the ... “Bo” Bryant Animal Shelter. “I have loved animals my whole ... with most of those animals being strays who needed a home. ... animals since I can’t take them all home!” , The CEO ...
(Date:9/18/2014)... Ottawa (September 18, 2014) A new expert ... released today by the Council of Canadian Academies, ... medicines for children. Each year about half of ... prescription drug. Much of this prescribing is done ... use), creating potential health risks., Children have historically ...
(Date:9/18/2014)... study analyses the survival rates in Spain of newborns with ... survival under 23 weeks is ,exceptional, although other factors such ... Experts from the Spanish Society of Neonatology have studied the ... under 26 weeks, taking into account that a newborn carried ... data have been drawn from the national database that gathers ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Improving medicines for children in Canada 2Health News:The viability of premature babies is minimal at 22 weeks' gestation 2
... test doesn,t single out those at high risk of trouble, ... screening for coronary artery disease is of no value for ... a new study finds. , Screening is expensive, at $1,000 ... 2 diabetes who had no symptoms of heart disease did ...
... Record 1,960 Eye and Tissue Donors in 2008 ... OneLegacy, the non-profit, federally designated organ and tissue ... area, has within the last year become the ... tens of thousands in need of cornea, bone, ...
... scientists at Beth Israel Deaconess Medical Center (BIDMC) have ... part of their 2009 Creativity Awards program, which supports ... prostate cancer. , The one-year awards were made ... with BIDMC the only institution in New England to ...
... April 14 While the number of ... the registry still only includes 38 percent of licensed ... Life America this year. Yet, according to a ... their decision to donate honored, even if their family ...
... Medical Plans, Inc., a leading provider-sponsored health insurer, covering ... announced an innovative Fracture Protection Pilot Program, in cooperation ... of Actonel, a prescription drug for the treatment and ... Alliance for Better Bone Health will cover the average ...
... (Nasdaq: ROCM ) will announce quarterly results after ... Company will then hold a quarterly conference call to discuss ... p.m. central time (5:00 p.m. eastern time).This call is being ... website at www.rocm.com . To listen ...
Cached Medicine News:Health News:Heart Screening Not Effective for Type 2 Diabetics 2Health News:Los Angeles Area Non-Profit OneLegacy Grows Into World's Largest Tissue Recovery Organization 2Health News:Los Angeles Area Non-Profit OneLegacy Grows Into World's Largest Tissue Recovery Organization 3Health News:Los Angeles Area Non-Profit OneLegacy Grows Into World's Largest Tissue Recovery Organization 4Health News:BIDMC scientists receive creativity awards from Prostate Cancer Foundation 2Health News:While the Majority of Americans Express Interest in Organ and Tissue Donation, Too Few Take Steps to Register as Donors 2Health News:While the Majority of Americans Express Interest in Organ and Tissue Donation, Too Few Take Steps to Register as Donors 3Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 2Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 3Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 4Health News:Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009 2